The Zeltia Group posts a 28% increase in net profit . Total debt declined by 10% on a year over year basis .

The Zeltia Group Reports Financial Results for the First Six Months of 2013 .

*.- Gross Yondelis® sales rose by 13.3% compared with the first half of 2012 .

*.- Gross sales of Yondelis® also advanced by 11% compared with the first quarter of this year thanks to the restoration of the supply of Caelyx ® .


Madrid, 23 July 2013:

The Zeltia Group, today announced financial results for the first half of 2013.

Gross sales of oncology drug Yondelis® rose by 13.3% compared to the same period in 2012.

This improvement was largely attributable to the restoration of the Caelyx

® supply, which had not been available since September 2011. Yondelis® is administered in combination with Caelyx® for the treatment of ovarian cancer. In 1H13, net sales of Yondelis® rose by 8% on a year over year basis, including price discounts applied by different European countries.

The gradual recovery of Yondelis ® sales was one of several factors that shaped the first-half results of the Zeltia Group. Also noteworthy is the 11% growth in gross sales between the first and second quarter of this year Sales in the consumer chemicals segment were again impacted by the consumer spending crisis, which, along with the poor weather in the first half, resulted in a 10.69% decline in net sales.

Total Group net sales in the first half of 2013 were 71.3 million euro compared with 72.7 million euro in the same period last year.

Group EBITDA in 1H13 was 19.6 million euro compared to. 20.8 million euro in 1H12 from continuing activities).With the Group’s greater focus in oncology, total net income attributable to the parent company was 14.4 million euro compared to 11.2 million euro in 1H1, translating to a 28% increase year over year.

Zeltia Group reduced its overall financial debt for the eleventh consecutive quarter. In June 30 2013, the Group reported gross debt of 104.6 million euro, 9.6 million euro less than at the start of 2013.

Crean bacterias magnéticas artificiales para diagnosticar cáncer de vías digestivas .

Científicos del Grupo de Bionanopartículas Metálicas (Bionanomet) pertenecientes al Instituto de la Biotecnología de la Universidad de Granada (UGR) están trabajando con bacterias magnéticas artificiales que podrían ser incluidas en los alimentos y usarse como fármacos naturales para poder diagnosticar enfermedades del sistema digestivo, como el cáncer.
   La utilización de alimentos como fármacos para diagnóstico es una aplicación "totalmente nueva", además de que este tipo de técnicas, no invasivas y no dolorosas para el paciente, son más precisas y sencillas de utilizar por parte de los médicos, según ha informado este miércoles en una nota la plataforma Divulgar Ciencia.

...

Tamoxifeno Reduce en un 50% la posibilidad de sufrir cáncer de mama y es una alternativa a la mastectomía preventiva .

Se trata, por tanto, de una alternativa a la mastectomía preventiva, como la realizada recientemente por Angelina Jolie para reducir las probabilidades de desarrollar cáncer debido a la herencia genética.
   Este fármaco, tal y como ha comentado a Europa Press el jefe de la Unidad de Obstetricia y Ginecología y de la Unidad de la Mujer del Hospital Ruber Internacional, Juan José Vidal, se utiliza tanto como tratamiento preventivo o como terapia complementaria a la cirugía o quimioterapia cuando el cáncer ya existe,
   En el primer caso, el tamoxifeno está indicado para todas aquellas mujeres que tienen un elevado componente genético familiar a padecer cáncer de mama y, en el segundo, está indicado para aquellas que tienen un tumor hormonodependiente.

...